nodes	percent_of_prediction	percent_of_DWPC	metapath
Thiabendazole—CYP1A1—Dacarbazine—melanoma	0.314	0.361	CbGbCtD
Thiabendazole—CYP1A2—Carmustine—melanoma	0.231	0.267	CbGbCtD
Thiabendazole—CYP1A2—Vemurafenib—melanoma	0.183	0.211	CbGbCtD
Thiabendazole—CYP1A2—Dacarbazine—melanoma	0.14	0.161	CbGbCtD
Thiabendazole—Lansoprazole—CYP1B1—melanoma	0.00391	0.777	CrCbGaD
Thiabendazole—Visual acuity reduced—Temozolomide—melanoma	0.00311	0.0288	CcSEcCtD
Thiabendazole—Cholestasis—Temozolomide—melanoma	0.00244	0.0225	CcSEcCtD
Thiabendazole—Liver injury—Temozolomide—melanoma	0.0022	0.0203	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.00201	0.0186	CcSEcCtD
Thiabendazole—Coordination abnormal—Carmustine—melanoma	0.00195	0.018	CcSEcCtD
Thiabendazole—Coordination abnormal—Temozolomide—melanoma	0.00189	0.0174	CcSEcCtD
Thiabendazole—Erythema multiforme—Vemurafenib—melanoma	0.00172	0.0159	CcSEcCtD
Thiabendazole—Hepatic failure—Dactinomycin—melanoma	0.00165	0.0153	CcSEcCtD
Thiabendazole—Chills—Vemurafenib—melanoma	0.00163	0.0151	CcSEcCtD
Thiabendazole—Hepatic failure—Temozolomide—melanoma	0.0015	0.0138	CcSEcCtD
Thiabendazole—Anaphylactic shock—Vemurafenib—melanoma	0.00129	0.0119	CcSEcCtD
Thiabendazole—Hepatocellular injury—Docetaxel—melanoma	0.00123	0.0114	CcSEcCtD
Thiabendazole—Hypotension—Vemurafenib—melanoma	0.00121	0.0112	CcSEcCtD
Thiabendazole—Haematuria—Bleomycin—melanoma	0.00117	0.0108	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.00114	0.0105	CcSEcCtD
Thiabendazole—Decreased appetite—Vemurafenib—melanoma	0.00112	0.0104	CcSEcCtD
Thiabendazole—Lansoprazole—ABCB1—melanoma	0.00112	0.223	CrCbGaD
Thiabendazole—Fatigue—Vemurafenib—melanoma	0.00111	0.0103	CcSEcCtD
Thiabendazole—Hypoaesthesia—Bleomycin—melanoma	0.0011	0.0101	CcSEcCtD
Thiabendazole—Hyperglycaemia—Carmustine—melanoma	0.00108	0.01	CcSEcCtD
Thiabendazole—Hyperglycaemia—Temozolomide—melanoma	0.00105	0.00968	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00103	0.00949	CcSEcCtD
Thiabendazole—Flushing—Bleomycin—melanoma	0.00102	0.00945	CcSEcCtD
Thiabendazole—Hepatic failure—Docetaxel—melanoma	0.000995	0.00919	CcSEcCtD
Thiabendazole—Chills—Bleomycin—melanoma	0.000989	0.00914	CcSEcCtD
Thiabendazole—Erythema multiforme—Dactinomycin—melanoma	0.000972	0.00898	CcSEcCtD
Thiabendazole—Hypoaesthesia—Carmustine—melanoma	0.000958	0.00885	CcSEcCtD
Thiabendazole—Flushing—Dactinomycin—melanoma	0.000954	0.00882	CcSEcCtD
Thiabendazole—Hypersensitivity—Vemurafenib—melanoma	0.000953	0.0088	CcSEcCtD
Thiabendazole—Asthenia—Vemurafenib—melanoma	0.000928	0.00857	CcSEcCtD
Thiabendazole—Visual impairment—Carmustine—melanoma	0.000928	0.00857	CcSEcCtD
Thiabendazole—Hypoaesthesia—Temozolomide—melanoma	0.000925	0.00855	CcSEcCtD
Thiabendazole—Chills—Dactinomycin—melanoma	0.000923	0.00852	CcSEcCtD
Thiabendazole—Pruritus—Vemurafenib—melanoma	0.000915	0.00845	CcSEcCtD
Thiabendazole—Visual impairment—Temozolomide—melanoma	0.000896	0.00828	CcSEcCtD
Thiabendazole—Flushing—Carmustine—melanoma	0.000893	0.00825	CcSEcCtD
Thiabendazole—Diarrhoea—Vemurafenib—melanoma	0.000885	0.00817	CcSEcCtD
Thiabendazole—Erythema multiforme—Temozolomide—melanoma	0.000879	0.00812	CcSEcCtD
Thiabendazole—Tinnitus—Temozolomide—melanoma	0.000867	0.00801	CcSEcCtD
Thiabendazole—Flushing—Temozolomide—melanoma	0.000863	0.00797	CcSEcCtD
Thiabendazole—Leukopenia—Bleomycin—melanoma	0.000859	0.00794	CcSEcCtD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—GPAM—melanoma	0.000857	0.045	CbGpPWpGaD
Thiabendazole—Dizziness—Vemurafenib—melanoma	0.000855	0.0079	CcSEcCtD
Thiabendazole—Chills—Temozolomide—melanoma	0.000835	0.00771	CcSEcCtD
Thiabendazole—Vomiting—Vemurafenib—melanoma	0.000822	0.00759	CcSEcCtD
Thiabendazole—Rash—Vemurafenib—melanoma	0.000815	0.00753	CcSEcCtD
Thiabendazole—Dermatitis—Vemurafenib—melanoma	0.000814	0.00752	CcSEcCtD
Thiabendazole—Headache—Vemurafenib—melanoma	0.00081	0.00748	CcSEcCtD
Thiabendazole—Leukopenia—Dactinomycin—melanoma	0.000801	0.0074	CcSEcCtD
Thiabendazole—Confusional state—Bleomycin—melanoma	0.00079	0.0073	CcSEcCtD
Thiabendazole—Vision blurred—Carmustine—melanoma	0.00079	0.00729	CcSEcCtD
Thiabendazole—Anaphylactic shock—Bleomycin—melanoma	0.000783	0.00724	CcSEcCtD
Thiabendazole—Nausea—Vemurafenib—melanoma	0.000768	0.00709	CcSEcCtD
Thiabendazole—Vision blurred—Temozolomide—melanoma	0.000763	0.00705	CcSEcCtD
Thiabendazole—Leukopenia—Carmustine—melanoma	0.00075	0.00693	CcSEcCtD
Thiabendazole—Anorexia—Bleomycin—melanoma	0.000747	0.0069	CcSEcCtD
Thiabendazole—Angioedema—Temozolomide—melanoma	0.00074	0.00683	CcSEcCtD
Thiabendazole—Hypotension—Bleomycin—melanoma	0.000732	0.00676	CcSEcCtD
Thiabendazole—Convulsion—Carmustine—melanoma	0.000726	0.00671	CcSEcCtD
Thiabendazole—Leukopenia—Temozolomide—melanoma	0.000725	0.0067	CcSEcCtD
Thiabendazole—Convulsion—Temozolomide—melanoma	0.000702	0.00648	CcSEcCtD
Thiabendazole—Anorexia—Dactinomycin—melanoma	0.000696	0.00643	CcSEcCtD
Thiabendazole—Confusional state—Carmustine—melanoma	0.000689	0.00637	CcSEcCtD
Thiabendazole—CYP1A1—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—melanoma	0.000685	0.036	CbGpPWpGaD
Thiabendazole—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000683	0.00631	CcSEcCtD
Thiabendazole—Decreased appetite—Bleomycin—melanoma	0.000681	0.00629	CcSEcCtD
Thiabendazole—Jaundice—Docetaxel—melanoma	0.000672	0.0062	CcSEcCtD
Thiabendazole—Confusional state—Temozolomide—melanoma	0.000666	0.00616	CcSEcCtD
Thiabendazole—Anaphylactic shock—Temozolomide—melanoma	0.000661	0.0061	CcSEcCtD
Thiabendazole—Anorexia—Carmustine—melanoma	0.000652	0.00602	CcSEcCtD
Thiabendazole—Feeling abnormal—Bleomycin—melanoma	0.000646	0.00596	CcSEcCtD
Thiabendazole—Hypotension—Carmustine—melanoma	0.000639	0.0059	CcSEcCtD
Thiabendazole—CYP1A2—Sulindac Metabolic Pathway—CYP1B1—melanoma	0.000636	0.0334	CbGpPWpGaD
Thiabendazole—Decreased appetite—Dactinomycin—melanoma	0.000635	0.00587	CcSEcCtD
Thiabendazole—Fatigue—Dactinomycin—melanoma	0.00063	0.00582	CcSEcCtD
Thiabendazole—Anorexia—Temozolomide—melanoma	0.00063	0.00582	CcSEcCtD
Thiabendazole—CYP1A1—Benzo(a)pyrene metabolism—CYP1B1—melanoma	0.000623	0.0328	CbGpPWpGaD
Thiabendazole—CYP1A1—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—melanoma	0.000623	0.0328	CbGpPWpGaD
Thiabendazole—Hypoaesthesia—Docetaxel—melanoma	0.000615	0.00569	CcSEcCtD
Thiabendazole—Somnolence—Carmustine—melanoma	0.000608	0.00562	CcSEcCtD
Thiabendazole—Feeling abnormal—Dactinomycin—melanoma	0.000602	0.00556	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Dactinomycin—melanoma	0.000597	0.00552	CcSEcCtD
Thiabendazole—Visual impairment—Docetaxel—melanoma	0.000596	0.00551	CcSEcCtD
Thiabendazole—Decreased appetite—Carmustine—melanoma	0.000594	0.00549	CcSEcCtD
Thiabendazole—Somnolence—Temozolomide—melanoma	0.000587	0.00543	CcSEcCtD
Thiabendazole—Erythema multiforme—Docetaxel—melanoma	0.000585	0.0054	CcSEcCtD
Thiabendazole—Dyspepsia—Temozolomide—melanoma	0.000582	0.00537	CcSEcCtD
Thiabendazole—Abdominal pain—Dactinomycin—melanoma	0.000578	0.00534	CcSEcCtD
Thiabendazole—Hypersensitivity—Bleomycin—melanoma	0.000577	0.00533	CcSEcCtD
Thiabendazole—Decreased appetite—Temozolomide—melanoma	0.000574	0.00531	CcSEcCtD
Thiabendazole—Flushing—Docetaxel—melanoma	0.000574	0.0053	CcSEcCtD
Thiabendazole—Fatigue—Temozolomide—melanoma	0.00057	0.00526	CcSEcCtD
Thiabendazole—Feeling abnormal—Carmustine—melanoma	0.000563	0.00521	CcSEcCtD
Thiabendazole—Asthenia—Bleomycin—melanoma	0.000562	0.00519	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Carmustine—melanoma	0.000559	0.00517	CcSEcCtD
Thiabendazole—Chills—Docetaxel—melanoma	0.000555	0.00513	CcSEcCtD
Thiabendazole—Pruritus—Bleomycin—melanoma	0.000554	0.00512	CcSEcCtD
Thiabendazole—CYP1A1—Melatonin metabolism and effects—MAP2—melanoma	0.000547	0.0288	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—GPAM—melanoma	0.000546	0.0287	CbGpPWpGaD
Thiabendazole—Feeling abnormal—Temozolomide—melanoma	0.000545	0.00503	CcSEcCtD
Thiabendazole—Abdominal pain—Carmustine—melanoma	0.000541	0.00499	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Temozolomide—melanoma	0.00054	0.00499	CcSEcCtD
Thiabendazole—Hypersensitivity—Dactinomycin—melanoma	0.000538	0.00497	CcSEcCtD
Thiabendazole—Asthenia—Dactinomycin—melanoma	0.000524	0.00484	CcSEcCtD
Thiabendazole—Abdominal pain—Temozolomide—melanoma	0.000522	0.00483	CcSEcCtD
Thiabendazole—Hypersensitivity—Carmustine—melanoma	0.000504	0.00465	CcSEcCtD
Thiabendazole—Diarrhoea—Dactinomycin—melanoma	0.0005	0.00462	CcSEcCtD
Thiabendazole—Vomiting—Bleomycin—melanoma	0.000498	0.0046	CcSEcCtD
Thiabendazole—Rash—Bleomycin—melanoma	0.000494	0.00456	CcSEcCtD
Thiabendazole—Dermatitis—Bleomycin—melanoma	0.000493	0.00456	CcSEcCtD
Thiabendazole—Asthenia—Carmustine—melanoma	0.000491	0.00453	CcSEcCtD
Thiabendazole—Hypersensitivity—Temozolomide—melanoma	0.000487	0.0045	CcSEcCtD
Thiabendazole—Leukopenia—Docetaxel—melanoma	0.000482	0.00445	CcSEcCtD
Thiabendazole—Asthenia—Temozolomide—melanoma	0.000474	0.00438	CcSEcCtD
Thiabendazole—Diarrhoea—Carmustine—melanoma	0.000468	0.00432	CcSEcCtD
Thiabendazole—Pruritus—Temozolomide—melanoma	0.000468	0.00432	CcSEcCtD
Thiabendazole—Convulsion—Docetaxel—melanoma	0.000467	0.00431	CcSEcCtD
Thiabendazole—Nausea—Bleomycin—melanoma	0.000465	0.0043	CcSEcCtD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—CYP1B1—melanoma	0.000465	0.0244	CbGpPWpGaD
Thiabendazole—Vomiting—Dactinomycin—melanoma	0.000465	0.00429	CcSEcCtD
Thiabendazole—Rash—Dactinomycin—melanoma	0.000461	0.00426	CcSEcCtD
Thiabendazole—Dizziness—Carmustine—melanoma	0.000452	0.00418	CcSEcCtD
Thiabendazole—Diarrhoea—Temozolomide—melanoma	0.000452	0.00418	CcSEcCtD
Thiabendazole—Confusional state—Docetaxel—melanoma	0.000443	0.00409	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—ARNT—melanoma	0.00044	0.0231	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—ARNT—melanoma	0.00044	0.0231	CbGpPWpGaD
Thiabendazole—Anaphylactic shock—Docetaxel—melanoma	0.000439	0.00406	CcSEcCtD
Thiabendazole—Dizziness—Temozolomide—melanoma	0.000437	0.00404	CcSEcCtD
Thiabendazole—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—melanoma	0.000437	0.023	CbGpPWpGaD
Thiabendazole—Vomiting—Carmustine—melanoma	0.000435	0.00402	CcSEcCtD
Thiabendazole—Nausea—Dactinomycin—melanoma	0.000434	0.00401	CcSEcCtD
Thiabendazole—Rash—Carmustine—melanoma	0.000431	0.00398	CcSEcCtD
Thiabendazole—Dermatitis—Carmustine—melanoma	0.000431	0.00398	CcSEcCtD
Thiabendazole—Headache—Carmustine—melanoma	0.000428	0.00396	CcSEcCtD
Thiabendazole—Vomiting—Temozolomide—melanoma	0.00042	0.00388	CcSEcCtD
Thiabendazole—Anorexia—Docetaxel—melanoma	0.000419	0.00387	CcSEcCtD
Thiabendazole—Rash—Temozolomide—melanoma	0.000417	0.00385	CcSEcCtD
Thiabendazole—Dermatitis—Temozolomide—melanoma	0.000416	0.00385	CcSEcCtD
Thiabendazole—Headache—Temozolomide—melanoma	0.000414	0.00382	CcSEcCtD
Thiabendazole—Hypotension—Docetaxel—melanoma	0.000411	0.00379	CcSEcCtD
Thiabendazole—Nausea—Carmustine—melanoma	0.000406	0.00375	CcSEcCtD
Thiabendazole—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—melanoma	0.000398	0.0209	CbGpPWpGaD
Thiabendazole—Nausea—Temozolomide—melanoma	0.000393	0.00363	CcSEcCtD
Thiabendazole—Somnolence—Docetaxel—melanoma	0.000391	0.00361	CcSEcCtD
Thiabendazole—Dyspepsia—Docetaxel—melanoma	0.000387	0.00357	CcSEcCtD
Thiabendazole—Decreased appetite—Docetaxel—melanoma	0.000382	0.00353	CcSEcCtD
Thiabendazole—Fatigue—Docetaxel—melanoma	0.000379	0.0035	CcSEcCtD
Thiabendazole—Feeling abnormal—Docetaxel—melanoma	0.000362	0.00335	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Docetaxel—melanoma	0.000359	0.00332	CcSEcCtD
Thiabendazole—CYP1A1—Estrogen metabolism—CYP1B1—melanoma	0.000358	0.0188	CbGpPWpGaD
Thiabendazole—CYP1A2—Melatonin metabolism and effects—MAP2—melanoma	0.000349	0.0183	CbGpPWpGaD
Thiabendazole—Abdominal pain—Docetaxel—melanoma	0.000347	0.00321	CcSEcCtD
Thiabendazole—Hypersensitivity—Docetaxel—melanoma	0.000324	0.00299	CcSEcCtD
Thiabendazole—CYP1A1—Tamoxifen metabolism—CYP1B1—melanoma	0.000317	0.0166	CbGpPWpGaD
Thiabendazole—Asthenia—Docetaxel—melanoma	0.000315	0.00291	CcSEcCtD
Thiabendazole—Pruritus—Docetaxel—melanoma	0.000311	0.00287	CcSEcCtD
Thiabendazole—Diarrhoea—Docetaxel—melanoma	0.000301	0.00278	CcSEcCtD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—CYP1B1—melanoma	0.000296	0.0156	CbGpPWpGaD
Thiabendazole—Dizziness—Docetaxel—melanoma	0.000291	0.00268	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—ARNT—melanoma	0.00028	0.0147	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—ARNT—melanoma	0.00028	0.0147	CbGpPWpGaD
Thiabendazole—Vomiting—Docetaxel—melanoma	0.000279	0.00258	CcSEcCtD
Thiabendazole—Rash—Docetaxel—melanoma	0.000277	0.00256	CcSEcCtD
Thiabendazole—Dermatitis—Docetaxel—melanoma	0.000277	0.00256	CcSEcCtD
Thiabendazole—Headache—Docetaxel—melanoma	0.000275	0.00254	CcSEcCtD
Thiabendazole—Nausea—Docetaxel—melanoma	0.000261	0.00241	CcSEcCtD
Thiabendazole—CYP1A1—Melatonin metabolism and effects—CYP1B1—melanoma	0.000245	0.0129	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—UGT2B10—melanoma	0.000229	0.012	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen metabolism—CYP1B1—melanoma	0.000228	0.012	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—UGT2B10—melanoma	0.00021	0.011	CbGpPWpGaD
Thiabendazole—CYP1A2—Tamoxifen metabolism—CYP1B1—melanoma	0.000202	0.0106	CbGpPWpGaD
Thiabendazole—CYP1A1—Melatonin metabolism and effects—EDN1—melanoma	0.000198	0.0104	CbGpPWpGaD
Thiabendazole—CYP1A1—Melatonin metabolism and effects—PRKCA—melanoma	0.000185	0.00974	CbGpPWpGaD
Thiabendazole—CYP1A1—Tryptophan metabolism—CYP1B1—melanoma	0.000169	0.00889	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CYP1B1—melanoma	0.000169	0.00889	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—CYP1B1—melanoma	0.000169	0.00889	CbGpPWpGaD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—STAT3—melanoma	0.000163	0.00858	CbGpPWpGaD
Thiabendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	0.000162	0.00854	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidation by Cytochrome P450—CYP17A1—melanoma	0.00016	0.00842	CbGpPWpGaD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—CYP1B1—melanoma	0.000158	0.00831	CbGpPWpGaD
Thiabendazole—CYP1A2—Melatonin metabolism and effects—CYP1B1—melanoma	0.000156	0.00819	CbGpPWpGaD
Thiabendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	0.000137	0.00718	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidation by Cytochrome P450—CYP1B1—melanoma	0.000135	0.00709	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—UGT2B10—melanoma	0.000134	0.00703	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—AKR1B10—melanoma	0.000133	0.00701	CbGpPWpGaD
Thiabendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	0.000132	0.00692	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—E2F1—melanoma	0.000131	0.00687	CbGpPWpGaD
Thiabendazole—CYP1A2—Melatonin metabolism and effects—EDN1—melanoma	0.000126	0.00663	CbGpPWpGaD
Thiabendazole—CYP1A2—Melatonin metabolism and effects—PRKCA—melanoma	0.000118	0.00621	CbGpPWpGaD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—melanoma	0.000113	0.00594	CbGpPWpGaD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—melanoma	0.000113	0.00593	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDK2—melanoma	0.000113	0.00593	CbGpPWpGaD
Thiabendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	0.000111	0.00582	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—melanoma	0.000108	0.00567	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—melanoma	0.000108	0.00567	CbGpPWpGaD
Thiabendazole—CYP1A2—Tryptophan metabolism—CYP1B1—melanoma	0.000108	0.00567	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—GPAM—melanoma	0.000105	0.0055	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—STAT3—melanoma	0.000104	0.00547	CbGpPWpGaD
Thiabendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	0.000104	0.00544	CbGpPWpGaD
Thiabendazole—CYP1A2—Oxidation by Cytochrome P450—CYP17A1—melanoma	0.000102	0.00537	CbGpPWpGaD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—CYP1B1—melanoma	0.000101	0.0053	CbGpPWpGaD
Thiabendazole—CYP1A1—Melatonin metabolism and effects—NFKB1—melanoma	9.56e-05	0.00503	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidative Stress—NFKB1—melanoma	9.31e-05	0.00489	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—melanoma	9.27e-05	0.00487	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—MAP2K1—melanoma	8.88e-05	0.00467	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—ACER3—melanoma	8.81e-05	0.00463	CbGpPWpGaD
Thiabendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	8.71e-05	0.00458	CbGpPWpGaD
Thiabendazole—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—melanoma	8.6e-05	0.00452	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—AKR1B10—melanoma	8.5e-05	0.00447	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	8.39e-05	0.00441	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—E2F1—melanoma	8.34e-05	0.00438	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—melanoma	7.95e-05	0.00418	CbGpPWpGaD
Thiabendazole—CYP1A1—Tryptophan metabolism—MDM2—melanoma	7.9e-05	0.00415	CbGpPWpGaD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	7.86e-05	0.00413	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—melanoma	7.62e-05	0.004	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—melanoma	7.22e-05	0.00379	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—melanoma	7.22e-05	0.00379	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDK2—melanoma	7.19e-05	0.00378	CbGpPWpGaD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—PTGS2—melanoma	7.13e-05	0.00375	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	7.06e-05	0.00371	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—melanoma	7.06e-05	0.00371	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—CYP17A1—melanoma	6.99e-05	0.00368	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—CYP17A1—melanoma	6.9e-05	0.00362	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—melanoma	6.66e-05	0.0035	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—melanoma	6.61e-05	0.00348	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—FASN—melanoma	6.23e-05	0.00328	CbGpPWpGaD
Thiabendazole—CYP1A2—Melatonin metabolism and effects—NFKB1—melanoma	6.1e-05	0.00321	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—melanoma	6e-05	0.00315	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—melanoma	5.93e-05	0.00312	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—melanoma	5.91e-05	0.00311	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—CYP1B1—melanoma	5.89e-05	0.00309	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—CYP1B1—melanoma	5.8e-05	0.00305	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—MAP2K1—melanoma	5.66e-05	0.00298	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—ACER3—melanoma	5.62e-05	0.00295	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—melanoma	5.52e-05	0.0029	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—melanoma	5.4e-05	0.00284	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—melanoma	5.4e-05	0.00284	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—melanoma	5.4e-05	0.00284	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIP4K2A—melanoma	5.34e-05	0.00281	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—melanoma	5.14e-05	0.0027	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—melanoma	5.14e-05	0.0027	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—melanoma	5.1e-05	0.00268	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—melanoma	5.07e-05	0.00266	CbGpPWpGaD
Thiabendazole—CYP1A2—Tryptophan metabolism—MDM2—melanoma	5.04e-05	0.00265	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—melanoma	4.86e-05	0.00255	CbGpPWpGaD
Thiabendazole—CYP1A1—PPARA activates gene expression—PPARG—melanoma	4.82e-05	0.00253	CbGpPWpGaD
Thiabendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—melanoma	4.72e-05	0.00248	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—melanoma	4.6e-05	0.00242	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—melanoma	4.6e-05	0.00242	CbGpPWpGaD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—PTGS2—melanoma	4.54e-05	0.00239	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—melanoma	4.5e-05	0.00237	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—CYP17A1—melanoma	4.46e-05	0.00234	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—CUBN—melanoma	4.45e-05	0.00234	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—CYP17A1—melanoma	4.4e-05	0.00231	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—melanoma	4.34e-05	0.00228	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—melanoma	4.25e-05	0.00223	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—melanoma	4.22e-05	0.00222	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—GPAM—melanoma	4.17e-05	0.00219	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ACER3—melanoma	3.92e-05	0.00206	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—melanoma	3.83e-05	0.00201	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—melanoma	3.78e-05	0.00199	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—CYP1B1—melanoma	3.75e-05	0.00197	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—CYP1B1—melanoma	3.7e-05	0.00195	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—UGT2B10—melanoma	3.59e-05	0.00189	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	3.54e-05	0.00186	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—melanoma	3.52e-05	0.00185	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—melanoma	3.44e-05	0.00181	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—melanoma	3.44e-05	0.00181	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—melanoma	3.44e-05	0.00181	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIP4K2A—melanoma	3.4e-05	0.00179	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—HS3ST5—melanoma	3.34e-05	0.00175	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—melanoma	3.28e-05	0.00172	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—melanoma	3.28e-05	0.00172	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—melanoma	3.25e-05	0.00171	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—melanoma	3.25e-05	0.00171	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CUBN—melanoma	2.84e-05	0.00149	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—melanoma	2.77e-05	0.00145	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	2.69e-05	0.00141	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—GPAM—melanoma	2.66e-05	0.0014	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PLCB4—melanoma	2.53e-05	0.00133	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ACER3—melanoma	2.5e-05	0.00131	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—FASN—melanoma	2.48e-05	0.0013	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIP4K2A—melanoma	2.38e-05	0.00125	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—SLC6A11—melanoma	2.38e-05	0.00125	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—MTAP—melanoma	2.31e-05	0.00122	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—UGT2B10—melanoma	2.29e-05	0.0012	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	2.26e-05	0.00119	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	2.26e-05	0.00119	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—HS3ST5—melanoma	2.13e-05	0.00112	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PHGDH—melanoma	2.06e-05	0.00108	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—LUM—melanoma	2.06e-05	0.00108	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—HPSE—melanoma	2.02e-05	0.00106	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CUBN—melanoma	1.98e-05	0.00104	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—SDHD—melanoma	1.92e-05	0.00101	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CSPG4—melanoma	1.92e-05	0.00101	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—BSG—melanoma	1.92e-05	0.00101	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GPAM—melanoma	1.86e-05	0.000975	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	1.71e-05	0.0009	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PLCB4—melanoma	1.61e-05	0.000847	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—FASN—melanoma	1.58e-05	0.000832	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PLA2G6—melanoma	1.58e-05	0.000829	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIP4K2A—melanoma	1.52e-05	0.000797	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—SLC6A11—melanoma	1.52e-05	0.000797	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—MTAP—melanoma	1.47e-05	0.000775	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.44e-05	0.000757	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—VCAN—melanoma	1.42e-05	0.000745	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.34e-05	0.000705	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—LUM—melanoma	1.31e-05	0.000691	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PHGDH—melanoma	1.31e-05	0.000691	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.29e-05	0.000681	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—HPSE—melanoma	1.29e-05	0.000677	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CUBN—melanoma	1.26e-05	0.000665	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—SDHD—melanoma	1.22e-05	0.000642	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—BSG—melanoma	1.22e-05	0.000642	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CSPG4—melanoma	1.22e-05	0.000642	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CYP17A1—melanoma	1.2e-05	0.000629	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GPAM—melanoma	1.18e-05	0.000622	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.18e-05	0.00062	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—ALB—melanoma	1.16e-05	0.000612	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GNA11—melanoma	1.13e-05	0.000594	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—FASN—melanoma	1.11e-05	0.000581	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—SLC5A5—melanoma	1.09e-05	0.000571	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CD44—melanoma	1.05e-05	0.000552	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GNAQ—melanoma	1.05e-05	0.000552	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.03e-05	0.00054	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.02e-05	0.000535	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CYP1B1—melanoma	1.01e-05	0.000529	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PLA2G6—melanoma	1.01e-05	0.000529	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—VCAN—melanoma	9.04e-06	0.000475	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—melanoma	8.88e-06	0.000467	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	8.55e-06	0.00045	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ABCB1—melanoma	8.29e-06	0.000436	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	8.26e-06	0.000434	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PRKCA—melanoma	7.63e-06	0.000401	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CYP17A1—melanoma	7.62e-06	0.000401	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ERCC2—melanoma	7.57e-06	0.000398	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	7.52e-06	0.000395	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	7.42e-06	0.00039	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GNA11—melanoma	7.2e-06	0.000378	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—FASN—melanoma	7.05e-06	0.00037	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—SLC5A5—melanoma	6.93e-06	0.000364	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GNAQ—melanoma	6.69e-06	0.000352	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CD44—melanoma	6.69e-06	0.000352	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.55e-06	0.000345	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	6.49e-06	0.000341	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CYP1B1—melanoma	6.42e-06	0.000337	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.27e-06	0.000329	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIK3CG—melanoma	5.97e-06	0.000314	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PPARG—melanoma	5.77e-06	0.000303	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.66e-06	0.000298	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ABCB1—melanoma	5.28e-06	0.000278	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIK3CD—melanoma	5.25e-06	0.000276	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ALB—melanoma	5.19e-06	0.000273	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PRKCA—melanoma	4.86e-06	0.000256	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ERCC2—melanoma	4.82e-06	0.000254	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIK3CB—melanoma	4.58e-06	0.000241	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PTGS2—melanoma	4.54e-06	0.000238	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4e-06	0.00021	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PTEN—melanoma	3.96e-06	0.000208	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIK3CG—melanoma	3.81e-06	0.0002	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PPARG—melanoma	3.68e-06	0.000193	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIK3CD—melanoma	3.35e-06	0.000176	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ALB—melanoma	3.31e-06	0.000174	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIK3CB—melanoma	2.92e-06	0.000153	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PTGS2—melanoma	2.89e-06	0.000152	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PIK3CA—melanoma	2.79e-06	0.000147	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PTEN—melanoma	2.52e-06	0.000133	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—AKT1—melanoma	2.28e-06	0.00012	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PIK3CA—melanoma	1.78e-06	9.35e-05	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—AKT1—melanoma	1.45e-06	7.64e-05	CbGpPWpGaD
